View Financial HealthTrivarX 配当と自社株買い配当金 基準チェック /06TrivarX配当金を支払った記録がありません。主要情報n/a配当利回り-22.4%バイバック利回り総株主利回り-22.4%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Dec 19TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 437,725,337 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listingお知らせ • Oct 27TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listingお知らせ • Oct 16TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listingお知らせ • Sep 26TrivarX Limited, Annual General Meeting, Nov 21, 2025TrivarX Limited, Annual General Meeting, Nov 21, 2025. Location: at the companys registered office, at 647 beaufort street, mount lawley, Australiaお知らせ • May 20TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 102,818,898 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 47,181,102 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Transaction Features: Subsequent Direct Listingお知らせ • Mar 17TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 102,818,898 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 47,181,102 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Transaction Features: Subsequent Direct Listingお知らせ • Oct 09TrivarX Limited, Annual General Meeting, Nov 28, 2024TrivarX Limited, Annual General Meeting, Nov 28, 2024. Location: 647 beaufort street, mount lawley, western australia., western australia. Australiaお知らせ • Sep 25TrivarX Limited Appoints John H. Mathias II as Non-Executive Director, Effective 1 October 2024TrivarX Limited announced that it has strengthened the composition of its Board with the appointment of Mr. John H. Mathias II as a Non-executive Director, effective 1 October 2024. Mr. Mathias is an accomplished healthcare focused operations and business development executive, with a clinical background in respiratory care. He has a demonstrated track record of success over a 30-year career in the US healthcare industry. Currently, he holds the role of Chief Development Officer at Medbridge Healthcare. MedBridge also has a number of professional partnerships that support adjacent services including hospital readmission reduction programs (HRRP), product and drug research, occupational health, professional services and therapeutic sleep offerings. As CDO, he plays a central role in building partnerships with stakeholders across the US healthcare system in the field of sleep medicine including hospitals, medical research institutions, clinical partnerships, and insurance companies. Prior to his role as CDO, Mr. Mathias also served as Chief Operating Officer and President of Sleep Services of America Inc., an entity of Johns Hopkins Health System, where he managed operations for sleep diagnostics and therapeutic coordination, oversaw strategic M&A and led a business turnaround which returned the division to profitability. Throughout his career, Mr. Mathias has been recognised for building and leading high-performing healthcare managers and sales teams and implementing strategic business plans to drive consistent growth in revenue and margin levels. With direct experience across several US healthcare industries, his core areas of expertise include contract management services for sleep and respiratory services, along with acute care hospital operations and developing improved patient solutions in the aged care industry. Mr. Mathias' appointment provides the Board with additional depth and expertise as it moves from clinical development towards regulatory approval and commercialisation for its proprietary MEB-001 algorithm with the effective screening of a current Major Depressive Episode (cMDE) in the US market.お知らせ • May 02TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 70,970,745 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,029,255 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Transaction Features: Subsequent Direct Listingお知らせ • Oct 06Medibio Limited, Annual General Meeting, Nov 29, 2023Medibio Limited, Annual General Meeting, Nov 29, 2023, at 09:00 W. Australia Standard Time. Location: COMO The Treasury, Executive Boardroom, 1 Cathedral Avenue, Perth WA 6000 Australiaお知らせ • Feb 18Medibio Limited Appoints Christopher Ntoumenopoulos as DirectorMedibio Limited announced the appointment of Christopher Ntoumenopoulos as Director of the company. The date of appointment is 15 February 2023.決済の安定と成長配当データの取得安定した配当: MDBI.Fの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: MDBI.Fの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場TrivarX 配当利回り対市場MDBI.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (MDBI.F)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Healthcare Services)1.2%アナリスト予想 (MDBI.F) (最長3年)n/a注目すべき配当: MDBI.Fは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: MDBI.Fは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: MDBI.Fの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: MDBI.Fが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/10 01:13終値2026/05/06 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋TrivarX Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Stuart RobertsPitt Street Research Pty Ltd.
お知らせ • Dec 19TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 437,725,337 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 27TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 16TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing
お知らせ • Sep 26TrivarX Limited, Annual General Meeting, Nov 21, 2025TrivarX Limited, Annual General Meeting, Nov 21, 2025. Location: at the companys registered office, at 647 beaufort street, mount lawley, Australia
お知らせ • May 20TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 102,818,898 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 47,181,102 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Transaction Features: Subsequent Direct Listing
お知らせ • Mar 17TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 102,818,898 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 47,181,102 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 09TrivarX Limited, Annual General Meeting, Nov 28, 2024TrivarX Limited, Annual General Meeting, Nov 28, 2024. Location: 647 beaufort street, mount lawley, western australia., western australia. Australia
お知らせ • Sep 25TrivarX Limited Appoints John H. Mathias II as Non-Executive Director, Effective 1 October 2024TrivarX Limited announced that it has strengthened the composition of its Board with the appointment of Mr. John H. Mathias II as a Non-executive Director, effective 1 October 2024. Mr. Mathias is an accomplished healthcare focused operations and business development executive, with a clinical background in respiratory care. He has a demonstrated track record of success over a 30-year career in the US healthcare industry. Currently, he holds the role of Chief Development Officer at Medbridge Healthcare. MedBridge also has a number of professional partnerships that support adjacent services including hospital readmission reduction programs (HRRP), product and drug research, occupational health, professional services and therapeutic sleep offerings. As CDO, he plays a central role in building partnerships with stakeholders across the US healthcare system in the field of sleep medicine including hospitals, medical research institutions, clinical partnerships, and insurance companies. Prior to his role as CDO, Mr. Mathias also served as Chief Operating Officer and President of Sleep Services of America Inc., an entity of Johns Hopkins Health System, where he managed operations for sleep diagnostics and therapeutic coordination, oversaw strategic M&A and led a business turnaround which returned the division to profitability. Throughout his career, Mr. Mathias has been recognised for building and leading high-performing healthcare managers and sales teams and implementing strategic business plans to drive consistent growth in revenue and margin levels. With direct experience across several US healthcare industries, his core areas of expertise include contract management services for sleep and respiratory services, along with acute care hospital operations and developing improved patient solutions in the aged care industry. Mr. Mathias' appointment provides the Board with additional depth and expertise as it moves from clinical development towards regulatory approval and commercialisation for its proprietary MEB-001 algorithm with the effective screening of a current Major Depressive Episode (cMDE) in the US market.
お知らせ • May 02TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 70,970,745 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,029,255 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 06Medibio Limited, Annual General Meeting, Nov 29, 2023Medibio Limited, Annual General Meeting, Nov 29, 2023, at 09:00 W. Australia Standard Time. Location: COMO The Treasury, Executive Boardroom, 1 Cathedral Avenue, Perth WA 6000 Australia
お知らせ • Feb 18Medibio Limited Appoints Christopher Ntoumenopoulos as DirectorMedibio Limited announced the appointment of Christopher Ntoumenopoulos as Director of the company. The date of appointment is 15 February 2023.